kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human LAG-3 / CD223 Protein, 100µg  

Recombinant human LAG-3 / CD223 Protein, 100µg

Recombinant Human LAG-3 / CD223 Protein, AA Leu 23 - Leu 450, expressed from human 293 cells (HEK293), His Tag (MALS verified)

Synonym: recombinant, human, protein LAG3, CD223, FDC

More details


Availability: within 7 days

442,00 €

Lymphocyte activation gene 3 protein (LAG3) is also known as CD antigen CD223 and protein FDC, which belongs to immunoglobulin (Ig) superfamily and contains 4 extracellular Ig-like domains. The LAG3 gene contains 8 exons. The sequence data, exon/intron organization, and chromosomal localization all indicate a close relationship of LAG3 to CD4. LAG3 /CD223 involved in lymphocyte activation. LAG3 /CD223 binds to HLA class-II antigens.

Recombinant Human LAG-3, His Tag (LA3-H5222) is expressed from human 293 cells (HEK293). It contains AA Leu 23 - Leu 450 (Accession # P18627-1).
Predicted N-terminus: Leu 23

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus, and has a calculated MW of 47.1 kDa. The predicted N-terminus is Leu23. The reducing (R) protein migrates as 55-60 kDa in SDS-PAGE due to glycosylation..

Less than 1.0 EU per μg by the LAL method.

>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Please refer to product data sheet.

See Certificate of Analysis for details of reconstitution instruction and specific concentration.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Clinical and Translational Updates

(1) "Tebotelimab Is Safe and Effective Across Multiple Cancer Types"
Cancer Discov (2023)
(2) "Checkpoint inhibition in hematologic malignancies"
Tsumura, Levis, Tuscano
Front Oncol (2023) 13, 1288172
(3) "Soluble immune checkpoints are elevated in patients with primary biliary cholangitis"
Gao, Wang, Guan et al
Eur J Med Res (2023) 28 (1), 477
Showing 1-3 of 1498 papers.


Authors: Zhang Wang et al.
Journal: US20210017279A1 2021
Application: Immunization
(2) "Anti-LAG-3 antibodies and methods of use thereof
Authors: NS Wilson, DA Savitsky, SM Jennings
Journal: US10844119B2 2020
Application: Flow cytometry
(3) "Anti-LAG3 antibodies, compositons comprising anti-LAG3 antibodies and methods of making and using anti-LAG3 antibodies"
Authors: R Stafford, et al
Journal: US20190330336A1 2019
Application: ELISA
(4) "Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy"
Authors: X Yu, et al
Journal: MAbs 2019
Application: Biopanning
(5) "Novel fusion polypeptide specific for Lag-3 and PD-1"
Authors: C Rothe, et al
Journal: US20190010231A1 2019
Application: ELISA